1,478,989 Shares in Edwards Lifesciences Co. (NYSE:EW) Bought by Seilern Investment Management Ltd

Seilern Investment Management Ltd acquired a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 1,478,989 shares of the medical research company's stock, valued at approximately $109,490,000. Edwards Lifesciences accounts for about 6.2% of Seilern Investment Management Ltd's investment portfolio, making the stock its 8th biggest holding. Seilern Investment Management Ltd owned approximately 0.25% of Edwards Lifesciences at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after buying an additional 308 shares in the last quarter. Peoples Bank KS bought a new stake in Edwards Lifesciences during the third quarter valued at about $40,000. Finally, Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $46,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.1 %

NYSE EW traded down $0.09 during trading hours on Monday, hitting $69.77. 5,031,232 shares of the company were exchanged, compared to its average volume of 4,364,863. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average price of $72.06 and a 200 day moving average price of $71.18. The stock has a market cap of $41.15 billion, a PE ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences's revenue was up 8.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.59 earnings per share. Analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the company's stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company's stock, valued at approximately $13,084,848.66. This represents a 11.18 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 33,000 shares of company stock worth $2,195,180 over the last 90 days. 1.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on EW shares. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a "hold" rating in a report on Thursday, December 5th. Evercore ISI dropped their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Wolfe Research cut shares of Edwards Lifesciences from a "peer perform" rating to an "underperform" rating and set a $60.00 price target for the company. in a research report on Thursday. Daiwa America cut Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 30th. Finally, Stifel Nicolaus lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company a "hold" rating in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and an average price target of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.